Open Access2020–2021 Drug Updates: Investigational Therapeutics in the Pipeline
Author(s) -
Donald C. Moore
Publication year - 2022
Publication title -
journal of the advanced practitioner in oncology
Language(s) - English
Resource type - Journals
eISSN - 2150-0886
pISSN - 2150-0878
DOI - 10.6004/jadpro.2022.13.3.21
Subject(s) - investigational drugs , medicine , drug , pipeline (software) , drug class , drug discovery , drug development , drug approval , intensive care medicine , pharmacology , bioinformatics , clinical trial , computer science , pathology , biology , programming language
During JADPRO Live Virtual 2021, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mechanism of action, a rethinking of how to approach treating a disease, or those that have recently received FDA Breakthrough Designation status that advanced practitioners should be aware of.